3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
NET
42
Gastrointestinal
42
Endocrine
42
Sarcoma
4
CNS
4
Thoracic
3
Other solid neoplasm
2
Lymphoid
2
Head & Neck
2
Gynecologic
2
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
10180
Triple Negative Breast Neoplasms
1045
Neoplasms
573
Ovarian Neoplasms
564
Neoplasm Metastasis
515
Colorectal Neoplasms
472
Carcinoma, Non-Small-Cell Lung
467
Prostatic Neoplasms
440
Lung Neoplasms
433
Pancreatic Neoplasms
312
Melanoma
299
Stomach Neoplasms
295
Breast Neoplasms, Male
257
Motor Activity
252
Colonic Neoplasms
238
Uterine Cervical Neoplasms
227
Endometrial Neoplasms
223
Head and Neck Neoplasms
218
Carcinoma, Intraductal, Noninfiltrating
217
Carcinoma, Renal Cell
192
Squamous Cell Carcinoma of Head and Neck
181
Sarcoma
176
Urinary Bladder Neoplasms
159
Esophageal Neoplasms
155
Brain Neoplasms
155
Breast Carcinoma In Situ
154
Lymphedema
148
Fatigue
136
Carcinoma, Ovarian Epithelial
134
Small Cell Lung Carcinoma
130
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastro-enteropancreatic neuroendocrine tumor
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled